News from spherix global insights A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 07, 2023, 18:12 ET Don't Mess with Success: U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights

Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global Insights,...

Jun 07, 2023, 16:34 ET Genentech's Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights

Genentech's Vabysmo got an 18-month head start over Regeneron's high dose Eylea (8mg aflibercept), but that lead time may be coming to a close within ...

May 23, 2023, 10:45 ET Riding the Early Adoption Wave Created by Ferring's Rebyota, Aimmune's Vowst, is Set to Provide a New Fecal Microbiota Transplant (FMT) Option for Patients Struggling with Recurrent Clostridioides Difficile, According to Spherix Global Insights

Prior to Ferring Pharmaceuticals' Rebyota, physicians interested in using fecal microbiota transplants (FMT) to treat patients with recurrent...

May 22, 2023, 19:09 ET The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights

The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S....

May 17, 2023, 13:52 ET Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights

In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC)....

May 15, 2023, 10:00 ET Spherix Global Insights Launches New Portal Providing Seamless Client Access to Subscribed Data and Insights

Spherix Global Insights, a leading provider of market research, business intelligence and advisory services to the global life sciences industry,...

May 08, 2023, 12:05 ET New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights

According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE)...

May 04, 2023, 19:10 ET Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda's Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC)...

Apr 14, 2023, 14:07 ET At Eighteen Months Post-Launch, Impel's Trudhesa Has Struggled to Keep Up with Pfizer's Nurtec ODT and AbbVie's Ubrelvy, According to Spherix Global Insights

Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the...

Apr 05, 2023, 11:45 ET U.S. Neurologists Cautiously Optimistic Following Accelerated Approval and Launch of Eisai/Biogen's Leqembi for Early Alzheimer's Disease, According to Spherix Global Insights

With the accelerated approval on January 6, 2023 for early Alzheimer's disease, Eisai/Biogen's Leqembi (lecanemab-irmb) became only the second...

Apr 03, 2023, 20:30 ET Sanofi/Regeneron's Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights

In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent ...

Mar 29, 2023, 15:13 ET Genentech's Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights

According to Spherix Global Insights' Launch Dynamix™: Vabysmo service, to no surprise, Regeneron's Eylea continues to lead the charge in both the...

Mar 27, 2023, 15:58 ET Familiarity with GSK's Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights

In the 32nd wave of ongoing tracking of the U.S. Renal Anemia market, Spherix surveyed 207 US nephrologists about overall patient management and...

Mar 24, 2023, 19:00 ET Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen's Respective IL-23 Entries, According to Spherix Global Insights

In 2021, Eli Lilly ("Lilly") announced it would forego pursuing a psoriasis indication for its IL-23 inhibitor mirikizumab, strategically focusing...

Mar 17, 2023, 12:35 ET Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights

When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant...

Mar 16, 2023, 17:53 ET At Fifteen Months Post-Launch, AbbVie's Qulipta Outperforms Pfizer's Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights

Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch...

Mar 15, 2023, 16:13 ET The IgA Nephropathy Landscape Has Experienced Rapid Changes Over Past Two Years with Increased Use of SGLT2 Inhibitors and Tarpeyo (Calliditas); More Change on The Way with Filspari (Travere) Launch, According to Spherix Global Insights

Focus on glomerular diseases has intensified over the past few years as products have advanced in development and nephrologists increasingly identify ...

Mar 15, 2023, 15:52 ET Early Launch Metrics for TG Therapeutics' Briumvi in RMS Trail Those of Novartis' In-Class Competitor Kesimpta, According to Spherix Global Insights

With the U.S. commercial launch of TG Therapeutics' Briumvi (ublituximab-xiiy) on January 26th, 2023 for the treatment of relapsing multiple...

Mar 09, 2023, 11:50 ET Despite Market Access Hurdles and Limited Familiarity Hampering Initial Uptake, Neurologists Project Robust Future Use of Relyvrio for the Treatment of ALS, According to Spherix Global Insights

With the FDA approval of Amylyx's Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) in September...

Feb 28, 2023, 15:40 ET US Neurologists Cautiously Optimistic About Potential Approval of Pfizer's Zavegepant for the Acute Treatment of Migraine, According to Spherix Global Insights

On February 16, The Lancet Neurology published the Phase 3 results of Pfizer's zavegepant for the acute treatment of migraine. The CGRP receptor...

Feb 28, 2023, 12:30 ET Apellis Ushers in a New Era of Geographic Atrophy Treatment with First Ever Approval, According to Spherix Global Insights

Apellis Pharmaceuticals recently made history with the approval of Syfovre (pegcetacoplan) for the treatment for Geographic Atrophy (GA). GA is an...

Feb 24, 2023, 15:00 ET Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences' Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech's Lucentis

Last summer, the introduction of biosimilar agents into ophthalmologists' armamentarium was a big event in the United States medical community....

Feb 24, 2023, 13:54 ET One Year Post-Launch of Argenx's Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights

Argenx's launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic approved...

Feb 22, 2023, 11:49 ET Introduction of AstraZeneca's Saphnelo (anifrolumab) has Expanded the Use of Biologic Agents in the Treatment of Systemic Lupus Erythematosus (SLE), Resulting in Gains for GSK's Benlysta (belimumab) as Well, According to Spherix Global Insights

Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the disease ...

Feb 17, 2023, 12:30 ET Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

According to Biogen's earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a ...